Technical Analysis for CGEN - Compugen Ltd.

Grade Last Price % Change Price Change
grade B 6.12 0.66% 0.04
CGEN closed up 0.66 percent on Friday, January 17, 2020, on 1.29 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CGEN trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Crossed Above 20 DMA Bullish 0.66%
Pocket Pivot Bullish Swing Setup 0.66%
20 DMA Resistance Bearish 5.70%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 5.70%
Inside Day Range Contraction 5.70%
Down 3 Days in a Row Weakness 5.70%
Down 4 Days in a Row Weakness 5.70%
Fell Below 20 DMA Bearish 4.97%
50 DMA Support Bullish 4.97%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Medicine Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Treatment Of Cancer Antibodies Cancers Autoimmune Diseases Multiple Sclerosis Antibody Rheumatoid Arthritis Multiple Myeloma Autoimmunity Monoclonal Antibody Autoimmune Disorders Compugen Treatment Of Multiple Sclerosis Antibody Therapy Fusion Protein

Is CGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.45
52 Week Low 2.74
Average Volume 230,824
200-Day Moving Average 4.26
50-Day Moving Average 5.76
20-Day Moving Average 5.95
10-Day Moving Average 6.03
Average True Range 0.32
ADX 13.38
+DI 21.25
-DI 18.19
Chandelier Exit (Long, 3 ATRs ) 5.49
Chandelier Exit (Short, 3 ATRs ) 6.40
Upper Bollinger Band 6.33
Lower Bollinger Band 5.58
Percent B (%b) 0.72
BandWidth 12.58
MACD Line 0.10
MACD Signal Line 0.12
MACD Histogram -0.0176
Fundamentals Value
Market Cap 312.93 Million
Num Shares 51.1 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -9.13
Price-to-Sales 1330.24
Price-to-Book 3.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.41
Resistance 3 (R3) 6.40 6.30 6.36
Resistance 2 (R2) 6.30 6.23 6.30 6.34
Resistance 1 (R1) 6.21 6.18 6.26 6.22 6.33
Pivot Point 6.11 6.11 6.13 6.11 6.11
Support 1 (S1) 6.02 6.04 6.07 6.03 5.91
Support 2 (S2) 5.92 5.99 5.92 5.90
Support 3 (S3) 5.83 5.92 5.88
Support 4 (S4) 5.84